Inside informationEnglish
OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Ose Immunotherapeutics
- Filed
- 08/12/2025, 07:30
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 113310_20251208